[Sonographic study of the effect of hyoscin-N-butylbromide on cholecystokinin stimulated gallbladder motility].
The influence of the spasmolytic agent Hyoscine-N-butylbromide on the Cholecystokinin induced gallbladder contraction was investigated by ultrasonography in 25 volunteers. Even at a dosage of 0.15 mg/kg i.v. administered Hyoscine-N-butylbromide inhibited significantly the gallbladder emptying. In the investigated dosage range up to 0.6 mg/kg Hyoscine-N-butylbromide a strong response relationship was found. Since after the application of Hyoscine-N-butylbromide 30 min. before Cholecystokinin injection no loss of efficacy was observed, a considerably longer duration of the spasmolytic effect can be assumed. Also the oral form of the spasmolytic (dragees, mean dosage 0.6 mg/kg, application 30 min. before Cholecystokinin) showed a significant inhibition of gallbladder motility.
D000328:Adult; D002086:Butylscopolammonium Bromide / Q000494:pharmacology*; D002766:Cholecystokinin; D004305:Dose-Response Relationship, Drug; D005260:Female; D005704:Gallbladder / Q000187:drug effects*; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D012602:Scopolamine Derivatives / Q000494:pharmacology*; D014463:Ultrasonography
D012602:Scopolamine Derivatives; D002086:Butylscopolammonium Bromide; D002766:Cholecystokinin
Sonographische Untersuchung der Wirkung von Hyoscin-N-Butylbromid auf die cholecystokinin-stimulierte Gallenblasenmotorik.